Platelet glycoprotein (GP) IIb/IIIa antagonists only prompt an overall 8.5% relative reduction in 30-day deaths or myocardial infarction in acute coronary syndromes (ACS), 1 and Quinn et al 1 suggested that this limited benefit may be due to factors such as antagonist-induced platelet activation. I suggest that limited benefits of GP IIb/IIIa inhibition are due basically to limited participation of platelets in ACS, although negative effects described by Quinn et al 1 are no doubt operative.
To the Editor:
Platelet glycoprotein (GP) IIb/IIIa antagonists only prompt an overall 8.5% relative reduction in 30-day deaths or myocardial infarction in acute coronary syndromes (ACS), 1 and Quinn et al 1 suggested that this limited benefit may be due to factors such as antagonist-induced platelet activation. I suggest that limited benefits of GP IIb/IIIa inhibition are due basically to limited participation of platelets in ACS, although negative effects described by Quinn et al 1 are no doubt operative.
Cases of ACS with and without elevated troponin levels treated by GP IIb/IIIa inhibition provide evidence for a limited role of platelets in ACS. Inhibition in troponin-negative cases was ineffective 2 or slightly worsened ACS, 3 but inhibition in troponin-positive patients yielded a reduction in deaths or infarction of 60% (average of 3 studies). 3 Effects of GP IIb/IIIa inhibition probably define roughly the significant involvement of platelets in ACS, and the striking improvement of only troponinpositive cases provides evidence that platelets are involved significantly only in troponin-positive cases, which comprise about a third (30.9%) of cases of ACS. 2 A study of abciximab supports significant platelet involvement only in troponin-positive cases. 2 The 6-month risk of death or nonfatal infarction in controls was 23.9% in troponin-positive and 7.9% in troponin-negative cases. Treatment with abciximab did not change the event rate in troponin-negative cases, but reduced the rate in troponin-positive cases to the level of troponin-negative cases.
As platelets are precursors of thromboses, the apparent absence of significant involvement of platelets in troponin-negative cases (about two thirds of ACS cases) raises questions about the validity of the plaque rupture/thromboses mechanism. In contrast, the spasm of resistance vessel (S-RV) concept can explain troponin findings. 4, 5 The concept asserts that symptoms in ischemic heart disease are due to S-RV and, in the minority of cases with significant platelet activation, vasoconstrictive agents from platelets add to S-RV and worsen prognosis.
However, the concept asserts that the major source of S-RV in ACS is stenotic coronary artery disease that causes ischemic injury and consequent ischemia-induced S-RV; a vicious cycle of S-RV, more ischemia, and more ischemia-induced S-RV favors infarction. Plaque rupture, often preexisting, would tend to worsen ischemia and favor platelet activation in some cases. Thromboses are attributed to stasis caused by S-RV-induced no-reflow plus intimal irregularities.
␣-adrenergic blockade should be useful in treating ACS. 5 The S-RV concept does give ischemia-induced S-RV the pivotal role in ACS, and ischemia-induced S-RV is reversed by ␣-adrenergic blockade. 5 
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